Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
FDA
Oct 4, 2024, 06:03 |
Drugs
FDA approved Neoadjuvant/Adjuvant Nivolumab for resectable NSCLC
FDA Approval Introduces New Treatment Options for Adults with Resectable Lung Cancer Lacking Key Genetic…
Oct 2, 2024, 15:39 |
Blog
Tanja Obradovic: FDA ODAC's decision on PD-1 Inhibitors in HER2- Negative Gastric Cancer
Tanja Obradovic shared a post on LinkedIn: "In highly anticipated discussion on September 26th FDA Oncologic Drugs…
Oct 2, 2024, 08:24 |
Blog
Tanja Obradovic: FDA just approved Osimertinib for adult patients with locally advanced, unresectable non-small cell lung cancer
Tanja Obradovic shared a post on LinkedIn: ''FDA just approved Osimertinib (Tagrisso), a third-generation EGFR-directed…
Oct 1, 2024, 10:44 |
Blog
The FDA-ASCO virtual workshop starts today!
ASCO posted on LinkedIn: "The FDA-ASCO virtual workshop starts tomorrow! Explore the impact of cancer…
Sep 28, 2024, 16:29 |
Blog
Thor Halfdanarson: A good review for those encountering patients with t-MN
Thor Halfdanarson, Vice President at North American Neuroendocrine Tumor Society, shared the following insights about a…
Sep 28, 2024, 07:02 |
Blog
Rahul Gosain: Osimertinib now FDA approved after LAURA Phase III study
Rahul Gosain shared the following on LinkedIn: “Osimertinib now FDA approved based off LAURA: Ph III,…
Sep 27, 2024, 15:04 |
Blog
Joshua Bauml: The U.S. FDA approved our targeted therapy in combination with for NSCLC with specific EGFR mutations
Joshua Bauml, Vice President, Lung Cancer Disease Area Stronghold (DAS) Leader, shared a post on…
Sep 26, 2024, 11:19 |
Blog
Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved - NCI Center for Cancer Research
NCI Center for Cancer Research shared a post on LinkedIn: "BREAKTHROUGH IN TREATMENT: In 2012, Senior…
Sep 24, 2024, 11:04 |
Blog
Stephen V Liu: The recent FDA approval of the MARIPOSA-2 regimen for EGFR NSCLC
Stephen V Liu shared a post on X: ''In this episode of the IASLC podcast…
Sep 24, 2024, 09:03 |
Blog
Vas Narasimhan: US FDA has approved our CDK4/6 inhibitor to reduce risk of recurrence in people with HR+/HER2 early breast cancer
Vas Narasimhan posted on LinkedIn: "I’m proud to share the news that the US FDA…
1
2
3
4
5
All:
934
Posts:
1 - 10
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Gavin Creel: Broadway Icon Dies After Battle with Rare Sarcoma at 48
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube